University Hospital Galway Pioneers Ground-Breaking Heart Valve Technology – First in Ireland!
University Hospital Galway is the first hospital in Ireland to use a new biological aortic heart valve.
Surgical aortic valve replacement involves removing a diseased aortic valve and replacing it with a new tissue-based or mechanical valve. This replacement allows oxygen-rich blood to flow efficiently from the heart.
The Avalus Ultra valve, created by Medtronic, is the new innovation. It simplifies the implantation process and empowers cardiac patients to enhance their quality of life.
On October 22, Noel O’Brien, a patient from Tynagh in County Galway, was the first to receive this valve. The surgery was performed by Professor Alan Soo and his team.
Noel shared his experience: “I was always active, but I felt tired and breathless over the past year. Now, I feel much more alive and energetic. I can’t wait to resume driving, farming, and walking my dog. This is a new lease of life for me.”
How has the introduction of the Avalus Ultra valve influenced cardiac care practices in Ireland?
Interview with Professor Alan Soo on the Introduction of the Avalus Ultra Aortic Valve at University Hospital Galway
Interviewer: Good day, Professor Soo. Thank you for joining us today. Can you tell us about the significance of University Hospital Galway being the first hospital in Ireland to utilize the Avalus Ultra biological aortic heart valve?
Professor Alan Soo: Thank you for having me. The introduction of the Avalus Ultra valve is a significant milestone for both our hospital and the wider medical community in Ireland. This valve simplifies the surgical implantation process, allowing us to perform procedures more efficiently and effectively. It represents a leap forward in treating patients suffering from aortic valve disease, ultimately enhancing their quality of life.
Interviewer: What challenges do patients face with traditional aortic valve replacements, and how does the Avalus Ultra address these issues?
Professor Alan Soo: Traditional aortic valve replacements can involve complex surgical techniques and sometimes have limitations regarding the durability of the valves. The Avalus Ultra has been designed specifically to improve upon these aspects, offering better long-term durability and a more streamlined implantation process. This means that not only are we able to provide faster surgeries, but patients can also look forward to an extended lifespan for their new valve.
Interviewer: We recently heard from Noel O’Brien, the first patient to receive the Avalus Ultra valve. His recovery has been quite remarkable. How does hearing these patient stories impact your team and the hospital?
Professor Alan Soo: Patient stories like Noel’s are incredibly rewarding for our entire team. They serve as a reminder of why we do what we do. Seeing a patient regain their vitality and enthusiasm for life after undergoing such a significant medical procedure is profoundly fulfilling. It’s a testament to the potential of this new valve and reinforces our commitment to advancing cardiac care.
Interviewer: Can you elaborate on the expected long-term benefits for patients like Noel who receive the Avalus Ultra valve?
Professor Alan Soo: Certainly. The Avalus Ultra valve is designed with longevity in mind, which is crucial for patients who are often seeking a long-term solution to aortic valve disease. With its enhanced durability, patients can anticipate fewer complications and potentially avoid the need for reoperation due to valve failure. Moreover, the improved quality of life that comes with better cardiac function can lead to increased physical activity, which is vital for overall health.
Interviewer: What does this advancement mean for the future of cardiac surgery in Ireland and the UK?
Professor Alan Soo: This advancement marks a pivotal moment not only for University Hospital Galway but also for cardiac surgery across Ireland and the UK. By integrating innovative technologies like the Avalus Ultra valve into our practices, we are setting a precedent for high-quality patient care. It opens the door for further advancements and research in cardiac treatments, ensuring that patients receive the best possible outcomes.
Interviewer: Thank you, Professor Soo, for your insights into this important development in cardiac care.
Professor Alan Soo: Thank you for having me. It’s always a pleasure to share our progress and dedication to improving patients’ lives.
Aortic valve disease causes the valve to narrow, making the heart work harder to pump blood. Patients with this condition often need valve replacement.
Professor Alan Soo commented on the Avalus Ultra valve, noting it represents a significant improvement over previous surgical biological valves. He emphasized its long-term durability and the benefits it brings to patients with aortic valve disease.
University Hospital Galway is proud to lead in offering this innovative treatment in Ireland and the UK.